** Shares of drug developer Vincerx Pharma VINC.O rise as much as 47% to $1.22
** VINC is planning to merge with QumulusAI, a private company that provides high-performance computing infrastructure for AI, the companies say
** The planned merger would make QumulusAI a publicly traded company; QumulusAI shareholders would own about 95% of the combined company, while VINC shareholders would own the rest
** Proposed deal values QumulusAI at around $285 million and Vincerx at around $15 million
** Following close of deal, QumulusAI would have a say on the combined company's management team and board of directors
** Stock fell 77.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.